Disease relevance of TIAF1

• RESULTS.: Breast cancer dominated coverage: 27% of MAJN and 35% of ENW stories mentioned breast cancer [1].
• These results suggest that the specific AR inhibitor SPR-210 will be a useful therapeutic agent for preventing and improving some diabetic complications, especially diabetic neuropathy and retinopathy, and therefore, can be discriminated from other AR inhibitors [2].
• These results demonstrate that SP-A binds to BCG and that uptake of these SP-A-BCG complexes is mediated in part by the SPR210 on rat macrophages and human monocytes [3].

High impact information on TIAF1

• A novel mRNA fusion between exon 32 of the myosin XVIIIA gene (MYO18A) at chromosome band 17q11 and exon 9 of FGFR1 was identified [4].
• We hypothesized that TIAF-1 plays a protective role against apoptosis during allograft rejection [5].
• Immunohistochemistry for TIAF-1 revealed expression in the inflammatory infiltrate and in tubular epithelial cells [5].
• Expression of TIAF-1 in the lymphocytes during chronic allograft rejection may be related to the predominance of a Th2 response in this condition [5].
• Furthermore, ectopic p53 blocked an ongoing apoptosis in U937 cells stably expressing TIAF1 [6].

Chemical compound and disease context of TIAF1

• In the current study we have investigated the role of SP-A in mediating uptake of bacillus Calmette-Guérin (BCG) by rat macrophages and human monocytes and have examined the role of the macrophage SPR210 in this process [3].

Biological context of TIAF1

• In contrast, overexpressed TIAF1 induces growth inhibition and apoptosis of monocytic U937 and various nonfibroblast cells [6].
• Suppression of TIAF1 expression by siRNA could not inhibit Ser15 phosphorylation in p53 in response to UV and etoposide [6].
• Moreover, the deterioration in motor nerve conduction velocity in diabetic rats was ameliorated by treatment with SPR-210 (1-30 mg/kg/day) accompanying the reduction in sorbitol content in the sciatic nerve [2].
• Sorbitol accumulation in isolated human erythrocytes was effectively inhibited by SPR-210 during incubation with 50 mM glucose (IC50 = 1.6 x 10(-8) M) [2].

Anatomical context of TIAF1

• Antisense TIAF1 mRNA significantly enhanced the proliferation of mink lung Mv1Lu epithelial cells [7].
• In contrast, like TGF-beta1, TIAF1 supported transforming growth of L929 fibroblasts [7].
• Strikingly, the vast majority of genes identified had not previously been associated with human TReg cells (including LGALS3, TIAF1, and TRAF1) [8].
• Inclusion of SPR210 antibodies blocked association of SP-A-BCG complexes, suggesting a role for SPR210 in mediating the interaction of SP-A-BCG with the macrophages [3].

Associations of TIAF1 with chemical compounds

• Oral administration of SPR-210 (1-30 mg/kg/day for 5 days) to streptozotocin-induced diabetic rats decreased the sorbitol contents in the sciatic nerve and lens (ED50 = 1.9 and 6.8 mg/kg/day, respectively) [2].
• SPR-210 showed a noncompetitive mechanism with respect to DL-glyceraldehyde against porcine lens AR [2].

Other interactions of TIAF1

• We previously isolated TIAF1 (TGF-beta1-induced antiapoptotic factor 1), which protects murine L929 fibroblasts from TNF cytotoxicity [7].
• Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats [2].

Analytical, diagnostic and therapeutic context of TIAF1

• High expression of TIAF-1 in chronic kidney and liver allograft rejection and in activated T-helper cells [5].
• METHODS: We examined TIAF-1 mRNA and protein expression in kidney and liver allograft biopsy specimens from patients with chronic or acute rejection by reverse transcriptase-polymerase chain reaction and immunohistochemistry [5].

References